Alcon Inc Dossier - Source-backed chat

Alcon Inc

ALCNYSE

SectorHealth Care

IndustryHealth Care Supplies

Beta (adjusted)0.90

Intrinsic Value $89.81median of 6 methods · middle span $76-$101based on filings through 31 Dec 2025

Market Price $64.75Price as of 30 Sep 2026

UndervaluedIntrinsic value is 39% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $31.3B

Enterprise Value $33.9B

Shares Outstanding 493.2M diluted

Moat Rating None

Next Earnings Date11 Nov 2026

Last ex-dividend6 May 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Alcon entered the second half of 2026 with broad-based constant-currency growth, accelerating equipment and ocular-health sales, improved core profitability, and higher full-year margin and core-EPS guidance. Recent launches including UNITY, PanOptix Pro and TRYPTYR provide identifiable growth drivers. The favorable view is moderated by only 1% first-half constant-currency growth in implantables, persistent competitive and cataract-market pressure, tariff exposure, and the $402 million pre-tax non-cash charge associated with discontinuing the PowerVision programs. The resulting risk-reward supports a Buy, but execution against the raised guidance is essential.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets15 analysts · as of 18 Aug 2026

Low · most bearish analyst$62.00

Mean target$85.24

High · most bullish analyst$103.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$60.0023%

Implantables remain pressured, cataract-market softness persists, tariffs exceed management's assumed range, and launch spending or additional pipeline setbacks prevent the expected margin expansion. Under this scenario, investors place greater weight on reported earnings volatility and the PowerVision discontinuation.

Base CaseCentral scenario

$85.2457%

Matches the consensus mean

Alcon delivers approximately within its FY2026 guidance of 5% to 7% constant-currency sales growth, 90 to 190 basis points of core operating-margin expansion, and 12% to 15% constant-currency core-EPS growth. UNITY, PanOptix Pro, TRYPTYR and other launches offset soft cataract conditions and weak implantables growth.

Bull CaseUpside scenario

$100.0020%

Recent launches sustain strong adoption, implantables growth improves from its first-half level, equipment and ocular health remain major contributors, and Alcon delivers near or above the upper ends of its 2026 sales, margin and core-EPS guidance ranges. Successful execution also demonstrates that the PowerVision discontinuation is isolated rather than evidence of broader pipeline weakness.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-half 2026 net sales increased 7% at constant currency, with both Surgical and Vision Care growing 7%.
Second-quarter core operating margin increased 160 basis points at constant currency, and management raised its full-year margin and core-EPS guidance.
First-half equipment/other and ocular-health sales increased 24% and 11%, respectively, at constant currency, demonstrating strong contribution from recent launches.
Alcon returned $538 million to shareholders during the first half and retained approximately $1.2 billion under its announced repurchase authorization.

Key Investment Risks

First-half implantables sales grew only 1% at constant currency amid competitive pressure and lower surgical-glaucoma sales.
Management continues to report softness in the cataract market, potentially limiting procedural and consumables growth.
The PowerVision programs were discontinued after unacceptable clinical outcomes, resulting in a $402 million pre-tax non-cash charge and highlighting development risk.
Management's outlook assumes a net FY2026 tariff impact of $40 million to $90 million and therefore remains sensitive to trade-policy changes.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.